Piramal Pharma Limited (PPLPHARMA.NS)
INR 211.04
(-0.0%)
INR 211.04
(-0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 19.91 Billion INR | -55.01% |
| 2022 | 44.26 Billion INR | 246.34% |
| 2021 | 12.78 Billion INR | 8.32% |
| 2020 | 11.79 Billion INR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 12.95 Billion INR | 10.47% |
| 2024 Q1 | 4.92 Billion INR | -4.14% |
| 2023 Q1 | 11.63 Billion INR | 0.55% |
| 2023 FY | 19.91 Billion INR | -55.01% |
| 2023 Q4 | 5.13 Billion INR | -57.22% |
| 2023 Q3 | 12.01 Billion INR | 0.74% |
| 2023 Q2 | 11.92 Billion INR | 2.5% |
| 2022 Q1 | 10.52 Billion INR | 174.75% |
| 2022 FY | 44.26 Billion INR | 246.34% |
| 2022 Q4 | 11.57 Billion INR | -0.92% |
| 2022 Q3 | 11.67 Billion INR | 11.25% |
| 2022 Q2 | 10.49 Billion INR | -0.24% |
| 2021 Q1 | 8.78 Billion INR | 0.0% |
| 2021 FY | 12.78 Billion INR | 8.32% |
| 2021 Q4 | -14.07 Billion INR | -254.14% |
| 2021 Q3 | 9.13 Billion INR | 0.03% |
| 2021 Q2 | 9.13 Billion INR | 3.94% |
| 2020 FY | 11.79 Billion INR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Biocon Limited | 40.9 Billion INR | 51.314% |
| Blue Jet Healthcare Limited | 531.85 Million INR | -3644.289% |
| Concord Biotech Limited | 1.45 Billion INR | -1264.25% |
| Dishman Carbogen Amcis Limited | 5.14 Billion INR | -286.875% |
| Jubilant Ingrevia Limited | 6.67 Billion INR | -198.561% |
| Lyka Labs Limited | 599.4 Million INR | -3222.284% |
| Panacea Biotec Limited | 1.99 Billion INR | -897.995% |
| SMS Lifesciences India Limited | 602.96 Million INR | -3202.668% |
| Supriya Lifescience Limited | 1.08 Billion INR | -1743.633% |
| Syngene International Limited | 5.99 Billion INR | -232.177% |
| TAKE Solutions Limited | 396.91 Million INR | -4917.258% |
| Zota Health Care Limited | 457.83 Million INR | -4249.602% |